Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.

Allen, A J; Kurlan, R M; Gilbert, D L; Coffey, B J; Linder, S L; Lewis, D W; Winner, P K; Dunn, D W; Dure, L S; Sallee, F R; Milton, D R; Mintz, M I; Ricardi, R K; Erenberg, G; Layton, L L; Feldman, P D; Kelsey, D K; Spencer, T J

Allen, A J; Kurlan, R M; Gilbert, D L; Coffey, B J; Linder, S L; Lewis, D W; Winner, P K; Dunn, D W; Dure, L S; Sallee, F R; Milton, D R; Mintz, M I; Ricardi, R K; Erenberg, G; Layton, L L; Feldman, P D; Kelsey, D K; Spencer, T J.

Affiliation

Allen AJ; Lilly Research Laboratories, Indianapolis, IN 46285, USA. allenaj@lilly.com

Neurology ; 65(12): 1941-9, 2005 Dec 27.

Article in En | MEDLINE | ID: mdl-16380617

Subject(s)

Attention Deficit Disorder with Hyperactivity/drug therapy; Propylamines/administration & dosage; Tic Disorders/drug therapy; Adolescent; Adrenergic Agonists/administration & dosage; Adrenergic Agonists/adverse effects; Atomoxetine Hydrochloride; Body Weight/drug effects; Child; Comorbidity; Double-Blind Method; Female; Heart Rate/drug effects; Humans; Male; Placebo Effect; Propylamines/adverse effects; Tachycardia/chemically induced; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Propylamines / Attention Deficit Disorder with Hyperactivity / Tic Disorders Type of study: Clinical_trials / Guideline Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Neurology Year: 2005 Document type: Article

Search on Google

XML

PubMed Links